1996
DOI: 10.1006/phrs.1996.0068
|View full text |Cite
|
Sign up to set email alerts
|

Repaglinide Preserves Nutrient-Stimulated Biosynthetic Activity in Rat Pancreatic Islets

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

2
12
0

Year Published

1999
1999
2019
2019

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 29 publications
(14 citation statements)
references
References 0 publications
2
12
0
Order By: Relevance
“…Thus, although both drugs have effects similar to glibenclamide in terms of stimulating insulin secretion, it appears that nateglinide and repaglinide are less toxic for ␤-cells. This is in line with previous findings demonstrating other distinct effects among sulfonylurea, repaglinide, and nateglinide (31,(43)(44)(45). The reason for these differences may be related to different binding characteristics to the K ATP channels (30,31,46).…”
Section: Discussionsupporting
confidence: 88%
“…Thus, although both drugs have effects similar to glibenclamide in terms of stimulating insulin secretion, it appears that nateglinide and repaglinide are less toxic for ␤-cells. This is in line with previous findings demonstrating other distinct effects among sulfonylurea, repaglinide, and nateglinide (31,(43)(44)(45). The reason for these differences may be related to different binding characteristics to the K ATP channels (30,31,46).…”
Section: Discussionsupporting
confidence: 88%
“…When rats were given an intravenous injection of 1 nmol/kg of the VPAC1-selective agonist [K15, R16, L27]VIP(1-7)/ GRF (8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27), it increased plasma insulin levels by twofold, but, consistent with the role of VPAC1 in enhancing hepatic glucose production, it also increased blood glucose levels by 14% 30 min after an IPGTT (data not shown). The VPAC1-selective agonist displayed dosedependent effects on intestinal water retention that were identical to those of VIP, whereas the effect of the VPAC2-selective agonist was much less.…”
Section: Vpac2 Agonist For Type 2 Diabetesmentioning
confidence: 71%
“…Insulin biosynthesis was studied in isolated rat islets using a modification of a previously described protocol (20). After an overnight culture, groups of 20 islets were preincubated in RPMI 1640 containing 3 mmol/l glucose for 30 min.…”
mentioning
confidence: 99%
“…However, in contrast to the sulphonylureas, repaglinide does not stimulate insulin release independently of its effects on beta-cell potassium channels, and does not inhibit insulin biosynthesis. 51,52,64,65 Another pharmacological difference of potential clinical importance between repaglinide and the sulphonylureas is that repaglinide augments insulin release from pancreatic islets in vitro only in the presence of glucose. 51,66 Thus, repaglinide enhances glucosemediated insulin release, and hence may be less likely to cause hypoglycaemia.…”
Section: Repaglinide: the ®Rst Hypoglycaemic Prandial Glucose Regulatormentioning
confidence: 99%